Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor

Leukemia Research

Volumn 35, Issue 9, 2011, Pages 1212-1218

  Yu, Wenjuan ^a   Wang, Jianxiang ^b   Jin, Jie ^a   Qian, Wenbin ^a   Qian, Jiejing ^a   Cheng, Yizhi ^a   Wang, Lei ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

17 Allylamino 17 demethoxygeldanamycin; Acute myeloid leukemia; Heat shock protein 90; Histone deacetylase inhibitor; KIT; Two hit

Indexed keywords

4 PHENYLBUTYRIC ACID; CD11B ANTIGEN; CD15 ANTIGEN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MICROSOMAL AMINOPEPTIDASE; PROTEIN KINASE B; STAT3 PROTEIN; STEM CELL FACTOR RECEPTOR; TANESPIMYCIN; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; AML1 GENE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; ETO GENE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INHIBITION KINETICS; LEUKEMIA CELL LINE; ONCOGENE; ONCOGENE C KIT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LEUKEMIA, MYELOID, ACUTE; MUTANT PROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION;

EID: 80051469142     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.05.014     Document Type: Article

References (26)

1. Reikvam H., Hatfield K., Kittang A.O., Hovland R., Bruserud Ø. Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. J Biomed Biotechnol 2011, 2011:104631. Epub 2011 February 22.
2. Sritana N., Auewarakul C.U. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups. Exp Mol Pathol 2008, 85:227-231.
3. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002, 8:S55-61.
4. Schulte T.W., Blagosklonny M.V., Ingui C., Neckers L. Disruption of the Raf-1-hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995, 270:24585-24588.
5. Whitesell L., Shifrin S.D., Schwab G., Neckers L.M. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res 1992, 52:1721-1728.
6. Whitesell L., Mimnaugh E.G., De Costa B., Myers C.E., Neckers L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994, 91:8324-8328.
7. Schulte T.W., Neckers L.M. The benzoquinone ansamycin 17-allylamino-17-demethoxy-geldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998, 42:273-279.
8. Yu Wenjuan, Rao Qing, Wang Min, Tian Zheng, Lin Dong, Liu Xiangrong Jianxiang Wang 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level. Leuk Res 2006, 30:575-582.
9. Wang J., Hoshino T., Redner R.L., Kajigaya S., Liu J.M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A 1998, 95:10860-10865.
10. Xu W., Mimnaugh E., Rosser M.F., Nicchitta C., Marcu M., Yarden Y., Neckers L. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein hsp90. J Biol Chem 2001, 276:3702-3708.
11. Solit D.B., Ivy S.P., Kopil C., Sikorski R., Morris M.J., Slovin S.F., Kelly W.K., DeLaCruz A., Curley T., Heller G., Larson S., Schwartz L., Egorin M.J., Rosen N., Scher H.I. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007, 13:1775-1782.
12. Beghini A., Bellini M., Magnani I., Colapietro P., Cairoli R., Morra E., Larizza L. STI 571 inhibition effect on Asn822Lys KIT-mediated signal transduction cascade. Exp Hematol 2005, 33:682-688.
13. Larizza L., Magnani I., Beghini A. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 2005, 46:247-255.
14. Beghini A., Magnani I., Ripamonti C.B., Larizza L. Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol J 2002, 3:157-163.
15. Fumo G., Akin C., Metcalfe D.D. Neckers L.17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004, 103:1078-1084.
16. Basso A.D., Solit D.B., Munster P.N., Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002, 21:1159-1166.
17. An W.G., Schulte T.W., Neckers L.M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000, 11:355-360.
18. Reikvam H., Ersvaer E., Bruserud O. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia. Curr Cancer Drug Targets 2009, 9:761-776.
19. Blagosklonny M.V. STI-571 must select for drug resistant cells but 'no cell breathes fire out of its nostrils like a dragon'. Leukemia 2002, 16:570-572.
20. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
21. Bauer S., Yu L.K., Demetri G.D., Fletcher J.A. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006, 66:9153-9161.
22. Goetz M.P., Toft D., Reid J., Ames M., Stensgard B., Safgren S., Adjei A.A., Sloan J., Atherton P., Vasile V., Salazaar S., Adjei A., Croghan G., Erlichman C. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005, 23:1078-1087.
23. Minucci S., Nervi C., Lo Coco F., Pelicci P.G. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?. Oncogene 2001, 20:3110-3115.
24. Bruserud Ø., Stapnes C., Tronstad K.J., Ryningen A., Anensen N., Gjertsen B.T. Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opin Ther Targets 2006, 10:51-68.
25. Quintás-Cardama A., Santos F.P., Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011, 25:226-235.
26. Fredly H., Stapnes Bjørnsen C., Gjertsen B.T., Bruserud Ø. Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia - a report of five cases. Hematology 2010, 15:338-343.